Literature DB >> 19560211

Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis.

Soheila Ajdary1, Farhad Riazi-Rad, Mohammad-Hossein Alimohammadian, Saeed-Reza Pakzad.   

Abstract

BACKGROUND: Leishmania (L.) tropica is the causative agent of anthroponotic cutaneous leishmaniasis (ACL) in Iran. The disease often heals within a year; however, the non-healing forms of disease are also known. The immunologic responses to L. major infection have been studied in depth, however little is known about the immune status of L. tropica-infected patients.
MATERIALS AND METHODS: This study was conducted to evaluate T-cell responses to Leishmania antigen in non-healing patients, patients with acute lesion, and healthy donors. Peripheral blood mononuclear cells (PBMC) were cultured with antigen and lymphoproliferative responses were determined. Cytokine profile including gamma interferon (IFN-gamma), interleukin (IL)-5, and IL-13 in supernatants of stimulated cells was also determined.
RESULTS: The results showed PBMC from both groups of patients proliferated vigorously in response to Leishmania antigens. The levels of IFN-gamma and IL-13 were comparable between patients with acute lesions and non-healing patients. Non-healing patients had significantly higher median levels of IL-5 than patients with acute lesions. The cells from healthy individuals did not respond to Leishmania antigens.
CONCLUSIONS: High levels of IFN-gamma, IL-5, and IL-13 in non-healing patients suggest a mixed Th1/Th2 response, whereas patients with acute lesion respond to infection by Th1-type response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19560211     DOI: 10.1016/j.jinf.2009.05.010

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

1.  Assessment of interferon-γ levels and leishmanin skin test results in persons recovered for leishmaniasis.

Authors:  Mohammad H Alimohammadian; Stephen L Jones; Haideh Darabi; Farhad Riazirad; Soheila Ajdary; Aliakbar Shabani; Mohammad A Rezaee; Mehdi Mohebali; Zohreh Hosseini; Farrokh Modabber
Journal:  Am J Trop Med Hyg       Date:  2012-07       Impact factor: 2.345

Review 2.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

3.  Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.

Authors:  Angamuthu Selvapandiyan; Ranadhir Dey; Sreenivas Gannavaram; Ines Lakhal-Naouar; Robert Duncan; Poonam Salotra; Hira L Nakhasi
Journal:  J Trop Med       Date:  2011-09-06

4.  Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.

Authors:  Katherine Kedzierska; Joan M Curtis; Sophie A Valkenburg; Lauren A Hatton; Hiu Kiu; Peter C Doherty; Lukasz Kedzierski
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

5.  Effect of trinitroglycerin therapy on serum zinc and copper levels and liver enzyme activities in BALB/c mice infected with Leishmania major MRHO/IR/75/ER.

Authors:  Mana Najafzade; Abbas Mosapour; Hossein Nahrevanian; Zahra Zamani; Seifoddin Javadian; Fatemeh Mirkhani
Journal:  Iran J Basic Med Sci       Date:  2015-03       Impact factor: 2.699

6.  Plasma levels of interlukin-4 and Interferon-γ in patients with chronic or healed cutaneous leishmaniasis.

Authors:  Ahmad Reza Taheri; Vahid Mashayekhi Goyonlo; Yalda Nahidi; Nasrin Moheghi; Jalil Tavakkol Afshari
Journal:  Iran J Basic Med Sci       Date:  2014-03       Impact factor: 2.699

Review 7.  A Historic Review of the Role of CD4+ T-Cell Subsets in Development of the Immune Responses against Cutaneous and Visceral Leishmaniases

Authors:  Mohammad Hossein Alimohmmadian; Soheila Ajdary; Fariborz Bahrami
Journal:  Iran Biomed J       Date:  2022-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.